IOmx Therapeutics AG

iOmx is a clinical-stage biotechnology company focused on developing next-generation targeted cancer immunotherapy treatments. The company leverages deep insights into tumor and myeloid biology, along with its proprietary iOTargTM target screening platform, to create novel treatments for prevalent solid tumor indications. iOmx translates unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs, aiming to develop drugs with single-agent activity that could serve as new backbone therapies across various modalities.

The company primarily serves cancer patients, targeting the oncology market with its innovative treatments. iOmx operates on a business model centered around drug discovery and development, making money through venture capital investments and potential future revenues from drug sales and partnerships.

Backed by international venture capital investors such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital, and M Ventures, iOmx is committed to shaping the future of cancer therapy through its comprehensive drug discovery and development expertise.

Keywords: cancer immunotherapy, tumor biology, myeloid biology, iOTargTM, biomarker-enabled, drug programs, single-agent activity, oncology market, venture capital, backbone therapies.